Steven Dickman is CEO of CBT Advisors, a boutique consulting firm in Cambridge, Massachusetts. CBT Advisors’ activities include corporate positioning and strategy; communications and fund-raising materials; and market analysis based on research and expert interviews. Clients have included public companies (Applied Biosystems, Alnylam, Biogen Idec, Celgene) and life-science venture funds as well as private life sciences companies in both Europe and the United States. Before founding CBT Advisors in 2003, Steve spent four years in venture capital with TVM Capital. There, Steve’s deals included Sirna Therapeutics, sold to Merck in 2006 for $1.1 billion. Earlier, he was a Knight Science Journalism Fellow at MIT, a freelance contributor to The Economist, Discover, Science, GEO and Die Zeit and the founding bureau chief for Nature in Munich, Germany. Fluent in German, Steve received his biochemistry degree cum laude from Princeton University.